1. 444 Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx). (September 2015) Authors: Scher, H.I.; Kelvin, J.; Lu, D.; Louw, J.; Packer, D.; Bambury, R.; Rathkopf, D.; Schreiber, N.; Brennan, R.; Prigozhina, N.; Brown, D.; Jendrisak, A.; Dugan, L.; Landers, M.; Lee, F.; Fleisher, M.; Marrinucci, D.; Dittamore, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Real world practice patterns for NSCLC patients in an Irish setting: a multi-centre study on targetable gene alterations and PD-L1 expression. (January 2019) Authors: Kee, W.; Mullally, W.; Dennehy, C.; Greene, J.; Kelly, D.; Bambury, R.; Bird, B. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗